Walleye Capital
SNDX icon

Walleye Capital’s Syndax Pharmaceuticals SNDX Stock Holding History

Walleye Capital’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$273K Sell
11,700
-2,200
-16% -$47.8K ﹤0.01% 3128
2025
Q4 		$292K Sell
13,900
-8,300
-37% -$145K ﹤0.01% 3336
2025
Q3 		$342K Sell
22,200
-6,400
-22% -$83.8K ﹤0.01% 2907
2025
Q2 		$268K Buy
+28,600
New +$315K ﹤0.01% 3146
2024
Q1 		– Sell
-6,500
Closed -$140K – 5865
2023
Q4 		$140K Buy
+6,500
New +$99.9K ﹤0.01% 3883

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Walleye Capital's SNDX Position: Q1 2026 in Review

Walleye Capital increased its Syndax Pharmaceuticals (SNDX) stake by 1,490% in Q1 2026, buying an estimated $7.84M and bringing the position to 384,973 shares worth $8.99M. The position accounts for 0.04% of the portfolio, ranked #445.

Walleye Capital first reported a position in SNDX in Q4 2022 and has held it in 11 quarters since. The position peaked at $11.5M in Q1 2023. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • Walleye Capital held 384,973 shares of Syndax Pharmaceuticals worth $8.99M as of Q1 2026.
  • Walleye Capital bought 360,768 Syndax Pharmaceuticals shares in Q1 2026, an estimated $7.84M.
  • Syndax Pharmaceuticals made up 0.04% of Walleye Capital's portfolio in Q1 2026, its #445 holding.
  • Walleye Capital first reported a position in Syndax Pharmaceuticals in Q4 2022 and has held it in 11 quarters since.
  • Walleye Capital's Syndax Pharmaceuticals position peaked at $11.5M in Q1 2023.
  • 246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.